CurtisAHansonMD

Hematopathology, Anatomic Pathology, Clinical Pathology

Hematopathology at Mayo Clinic

Dr. Hanson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Curtis Hanson is a pathology specialist based in Rochester, MN, with subspecialties in hematopathology, anatomic pathology, and clinical pathology. He completed his medical education at the University of Iowa Roy J. and Lucille A. Carver College of Medicine in 1982, followed by a and a residency in anatomic and clinical pathology and fellowship in hematopathology at the University of Minnesota. Dr. Hanson is experienced in hemoglobin electrophoresis, hematopathology, pathology, laboratory management, and laboratory hematology. He has authored several publications including studies on monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia, some of which have been cited in medical literature.

University of MinnesotaResidency, Pathology-Anatomic and Clinical, 1982 - 1987
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1982

PubMed

Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.
Paul J Hampel, Kari G Rabe, Yucai Wang, Steven R Hwang, Saad S Kenderian
Leukemia. 2025-02-01
Regulatory requirements for laboratory developed tests in the United States.
Shannon A Bennett, Chelsea M Conn, Hillary E Gill, Brenda K Holmen, Tasha M McDevitt
Journal of Immunological Methods. 2025-01-27
1 citations
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan O'Brien
Blood Advances. 2025-01-14

Abstracts/Posters

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
Curtis A. Hanson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

A Prospective Evaluation of Vitamin B1 (thiamine) Level in Myeloproliferative Neoplasms: Clinical Correlations and Impact of JAK2 Inhibitor Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Germline JAK2 GGCC (46/1) Haplotype and Survival Among 414 Molecularly-Annotated Patients with Primary Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Centralized Cardiac Monitoring Center Developed by Cleveland ClinicOctober 25th, 2017
Primary Care Docs Spending About Half Their Work Days Interacting with EHRsOctober 13th, 2017
Lab Rules Firing at the Time of Test Order; Possible on the LIS?October 9th, 2017
Join now to see all